Immunomic Therapeutics, Inc. (ITI) is a privately-held clinical stage biotechnology company pioneering the study of the Universal Intracellular Targeted Expression (UNITE) nucleic acid immunotherapy platform.

Biotechnology

Immunomic Therapeutics

Immunomic Therapeutics' headquarters in Rockville, MD, United States

This department oversees and coordinates various projects and initiatives to ensure efficient operations and successful outcomes.

Program Management

The Scientific Team at Immunomic Therapeutics drives the development and innovation of the UNITE platform by conducting cutting-edge research, designing clinical studies, and analyzing experimental data. This team, comprising leading experts and advisors, works collaboratively to advance the company's immunotherapy solutions from the laboratory to clinical application.

Scientific Team

The Directors team at Immunomic Therapeutics, Inc. provides strategic leadership and governance, ensuring the company advances its clinical-stage biotechnology innovations. They oversee various functions, including research, development, regulatory affairs, and finance, to drive the success of the UNITE nucleic acid immunotherapy platform.

Directors

The Leadership Team at Immunomic Therapeutics is responsible for setting the strategic direction and overseeing the execution of the company's clinical programs and business initiatives. This team, comprising key executives like the CFO and Chief Scientific Officer, ensures regulatory compliance, drives scientific innovation, and manages financial health to advance the development of the UNITE nucleic acid immunotherapy platform. Their collaborative efforts aim to propel the company towards successful clinical outcomes and sustainable growth in the biotechnology sector.

Leadership Team

This department focuses on ensuring product quality and compliance through systematic testing and evaluation processes.

People (2)

Jobs (0)

Other teams

Scientific Team

Directors

Leadership Team

Quality Assurance